Literature DB >> 7402688

Headache provocation by continuous intravenous infusion of histamine. Clinical results and receptor mechanisms.

Annette Aebelholt Krabbe1, Jes Olesen.   

Abstract

Histamine, 0.16, 0.33 and 0.66 microgram/kg/min, was infused intravenously to 13 normal non-headache-prone volunteers, 10 patients with chronic muscle contraction headache and 25 patients with common migraine. In the normal group no patients developed pulsating headache. In the migraine group 13 patients developed severe, 9 patients moderate and 2 patients mild pulsating headache, and only 1 patient failed to develop headache at all. The muscle contraction headache patients responded intermediately. At each infusion rate the headache was of constant quality and severity as long as the infusion continued, but disappeared shortly after its termination. Injection of an H1 blocking agent, mepyramine, almost immediately abolished the headache. The H2 blocker cimetidine was much less effective, but still significantly better than placebo. The i.v. histamine infusion test is a useful model for the study of experimental vascular headache.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7402688     DOI: 10.1016/0304-3959(88)90012-7

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  21 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Possible role of histamine (H1- and H2-) receptors in the regulation of meningeal blood flow.

Authors:  Mária Dux; Nina Schwenger; Karl Messlinger
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

3.  Hypothalamic and basal ganglia projections to the posterior thalamus: possible role in modulation of migraine headache and photophobia.

Authors:  R Kagan; V Kainz; R Burstein; R Noseda
Journal:  Neuroscience       Date:  2013-06-25       Impact factor: 3.590

Review 4.  Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.

Authors:  Ann C Raddant; Andrew F Russo
Journal:  Expert Rev Mol Med       Date:  2011-11-29       Impact factor: 5.600

5.  Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine.

Authors:  L H Lassen; L L Thomsen; C Kruuse; H K Iversen; J Olesen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Plasma serotonin in patients with chronic tension headaches.

Authors:  M Anthony; J W Lance
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

Review 7.  Migraine: where and how does the pain originate?

Authors:  Karl Messlinger
Journal:  Exp Brain Res       Date:  2009-03-14       Impact factor: 1.972

Review 8.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 9.  The role of nitric oxide in vascular headache.

Authors:  Paul-Hugo M van der Kuy; Joseph J Lohman
Journal:  Pharm World Sci       Date:  2003-08

Review 10.  5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives.

Authors:  J R Fozard; H O Kalkman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.